MDT

89.75

+0.12%↑

VEEV

280.84

-0.41%↓

A

112.08

-1.67%↓

WBA

11.51

+0.26%↑

HQY

96.98

-0.63%↓

MDT

89.75

+0.12%↑

VEEV

280.84

-0.41%↓

A

112.08

-1.67%↓

WBA

11.51

+0.26%↑

HQY

96.98

-0.63%↓

MDT

89.75

+0.12%↑

VEEV

280.84

-0.41%↓

A

112.08

-1.67%↓

WBA

11.51

+0.26%↑

HQY

96.98

-0.63%↓

MDT

89.75

+0.12%↑

VEEV

280.84

-0.41%↓

A

112.08

-1.67%↓

WBA

11.51

+0.26%↑

HQY

96.98

-0.63%↓

MDT

89.75

+0.12%↑

VEEV

280.84

-0.41%↓

A

112.08

-1.67%↓

WBA

11.51

+0.26%↑

HQY

96.98

-0.63%↓

Search

Regeneron Pharmaceuticals Inc

Închisă

SectorSănătate

546.45 0.72

Rezumat

Modificarea prețului

24h

Curent

Minim

544.48

Maxim

551.77

Indicatori cheie

By Trading Economics

Venit

-109M

809M

Vânzări

-761M

3B

P/E

Medie Sector

14.515

39.857

EPS

8.22

Randament dividend

0.67

Marjă de profit

26.701

Angajați

15,158

EBITDA

-54M

1B

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+34.61% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

0.67%

2.42%

Următoarele câștiguri

1 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-13B

62B

Deschiderea anterioară

545.73

Închiderea anterioară

546.45

Sentimentul știrilor

By Acuity

33%

67%

87 / 376 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Regeneron Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

19 mai 2025, 11:55 UTC

Achiziții, Fuziuni, Preluări

Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million

29 apr. 2025, 11:07 UTC

Câștiguri

Regeneron 1Q Profit Rises, Revenue Falls; FY25 CapEx Target Trimmed

13 iun. 2025, 21:42 UTC

Achiziții, Fuziuni, Preluări

Anne Wojcicki Wins Bidding for 23andMe -- 2nd Update

13 iun. 2025, 20:45 UTC

Achiziții, Fuziuni, Preluări

23andMe: TTAM Makes Binding Commitments for Additional Consumer Protections and Privacy Safeguards

13 iun. 2025, 20:34 UTC

Achiziții, Fuziuni, Preluări

Anne Wojcicki Wins Bidding for 23andMe -- Update

13 iun. 2025, 20:14 UTC

Achiziții, Fuziuni, Preluări

Nonprofit Controlled By 23andMe Co-Founder Anne Wojcicki Would Buy the DNA-Testing Company for $305 Million -- WSJ

13 iun. 2025, 20:14 UTC

Achiziții, Fuziuni, Preluări

Anne Wojcicki Wins Bidding for 23andMe -- WSJ

13 iun. 2025, 20:14 UTC

Achiziții, Fuziuni, Preluări

Regeneron Walks Away From 23andMe Acquisition After Wojcicki's Higher Bid -- WSJ

5 iun. 2025, 01:41 UTC

Achiziții, Fuziuni, Preluări

23andMe's Former CEO Pushes Purchase Price Nearly $50 Million Higher -- WSJ

30 mai 2025, 08:58 UTC

Acțiuni populare

Stocks to Watch Friday: Dell, Marvell, Gap, Ulta -- WSJ

30 mai 2025, 08:56 UTC

Market Talk

Sanofi, Regeneron Hit by Trial Disappointment -- Market Talk

19 mai 2025, 17:52 UTC

Top știri
Achiziții, Fuziuni, Preluări

Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million -- 2nd Update

19 mai 2025, 16:13 UTC

Achiziții, Fuziuni, Preluări

Regeneron Is Buying 23andMe. The Deal Is a Head Scratcher. -- Barrons.com

19 mai 2025, 14:42 UTC

Top știri
Achiziții, Fuziuni, Preluări

Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million -- 2nd Update

19 mai 2025, 13:33 UTC

Top știri
Achiziții, Fuziuni, Preluări

Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million -- Update

19 mai 2025, 11:10 UTC

Achiziții, Fuziuni, Preluări

Regeneron: To Ensure Compliance With 23andMe Consumer Privacy Policies, Applicable Laws on Customer Data >REGN

19 mai 2025, 11:10 UTC

Achiziții, Fuziuni, Preluări

Regeneron: 23andMe Transaction Expected to Close in 3Q >REGN

19 mai 2025, 11:09 UTC

Achiziții, Fuziuni, Preluări

Regeneron: To Continue All 23andMe Consumer Genome Services Uninterrupted >REGN

19 mai 2025, 11:08 UTC

Achiziții, Fuziuni, Preluări

Regeneron: Named Successful Bidder in Bankruptcy Auction for Substantially All Assets of 23andMe >REGN

29 apr. 2025, 18:04 UTC

Market Talk
Câștiguri

Regeneron Sinks As Sales Of Key Eye Medication Tumble -- Market Talk

29 apr. 2025, 14:39 UTC

Market Talk
Câștiguri

Regeneron's Eylea Setback Drags Stock as Investor Frustrations Mount -- Market Talk

29 apr. 2025, 14:29 UTC

Câștiguri

Regeneron Stock Plummets After Earnings Miss -- Barrons.com

29 apr. 2025, 13:11 UTC

Câștiguri

Regeneron Stock Plummets After Earnings Miss -- Barrons.com

29 apr. 2025, 10:32 UTC

Câștiguri

Regeneron Pharma Cuts 2025 CapEx to $850M-$950M >REGN

29 apr. 2025, 10:30 UTC

Câștiguri

Regeneron Pharma 1Q Rev $3.03B >REGN

29 apr. 2025, 10:30 UTC

Câștiguri

Regeneron Pharma 1Q Net $808.7M >REGN

29 apr. 2025, 10:30 UTC

Câștiguri

Regeneron Pharma 1Q EPS $7.27 >REGN

29 apr. 2025, 10:30 UTC

Câștiguri

Regeneron Pharma 1Q Adj EPS $8.22 >REGN

22 apr. 2025, 10:51 UTC

Top știri

Drug Companies Step Up 'Make in America' Plans to Counter Tariffs -- WSJ

28 feb. 2025, 12:00 UTC

Top știri

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

Comparație

Modificare preț

Regeneron Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

34.61% sus

Prognoză pe 12 luni

Medie 730.29 USD  34.61%

Maxim 900 USD

Minim 535 USD

În baza a 24 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruRegeneron Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

24 ratings

17

Cumpărare

6

Păstrare

1

Vânzare

Scor tehnic

By Trading Central

542.44 / 599.76Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Strong Bullish Evidence

Termen lung

Weak Bearish Evidence

Sentiment

By Acuity

87 / 376 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.